RLYB Rallybio
- 1.830
- -0.070-3.68%
- 1.810
- -0.020-1.10%
Rallybio News
Express News | Rallybio Files Prospectus Related To Disposition From Time To Time Of Up To 3.6M Shares Of Common Stock By Selling Stockholder
Express News | Rallybio Files Prospectus Related to Disposition From Time to Time of up to 3.6 Mln Shares of Common Stock by Selling Stockholder - SEC Filing
Express News | HC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $9 Price Target
Buy Rating Affirmed for Rallybio: Promising FNAIT Drug Candidate and Strong Financials
Rallybio's Advancements and Financial Health Prompt a Buy Rating From Analyst Jonathan Wolleben
Rallybio | 10-Q: Quarterly report
Express News | Rallybio Corp: On Track to Initiate Rlyb212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of Fnait in 2H 2024
Rallybio: $94.2 M in Cash, Cash Equivalents, and Marketable Securities as of March 31 Provides Runway Into Mid-2026 >RLYB
Rallybio: $94.2 M in Cash, Cash Equivalents, and Marketable Securities as of March 31 Provides Runway Into Mid-2026 >RLYB
Express News | Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
Express News | Rallybio Q1 Operating Expenses USD 19.787 Million
Express News | Rallybio Q1 Net Income USD -19.029 Million
Express News | Rallybio Q1 Income From Operations USD -19.787 Million
Press Release: Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates - On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024
Express News | Rallybio Q1 Basic EPS USD -0.47
Rallybio 1Q Loss $19M >RLYB
Rallybio 1Q Loss $19M >RLYB
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today
Express News | JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target
Rallybio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/18/2024 346.93% JMP Securities → $8 Reiterates Market Outperform → Market Outperform 04/11/2024 514.53%
Buy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT Treatment
Rallybio Corporation Announces FNAIT Systematic Literature Review And Meta-Analysis Presented At The Academy Of Managed Care Pharmacy 2024 Annual Meeting
- Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women -- Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization -R
Analysis
Price Target
No Data
